Regulation

MHRA Flags Updated Field Safety Notices for Kimal PLC Medical Devices

The MHRA has reissued Field Safety Notices for Kimal PLC's Namic Manifolds and Angiograph Control Syringes, impacting medical device components within procedure packs. Manufacturers integrating these components must verify compliance immediately.

By SF News Editorial · 1 May 2026

AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →

London, United Kingdom — 01 May 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has published an update to existing Field Safety Notices (FSNs) concerning specific medical devices manufactured by Kimal PLC. The updated notices, issued on 1st May 2026, pertain to 'Namic White Star Handle Manifolds included in Medline’s Namic Systems' (Kimal Ref: GLB101838 – Issue 2) and 'Angiograph Control Syringe with Rotating Adaptor (RA) fitting in Kimal Procedure Pack' (Kimal Ref: GLB101836 – Issue 3). These FSNs, referencing MHRA numbers 39391570 and 39392623 respectively, signify critical information that should prompt immediate action from all manufacturers and distributors incorporating these items or related components into their own medical device offerings.

The MHRA explicitly states that all recipients of an FSN from a manufacturer must act upon it, categorising its own publication as purely for informational purposes regarding these specific recalls. This highlights the direct responsibility placed on supply chain participants to maintain a robust intelligence system for identifying and responding to such notices. Failure to engage with these amended FSNs could place downstream manufacturers in a precarious position regarding product safety and regulatory adherence.

The affected products include components that are frequently integrated into broader medical procedure packs. This necessitates a thorough review by all medical device manufacturers to identify potential exposure. The implications extend beyond direct supply relationships, affecting any entity whose products rely on or interact with the specified Kimal PLC components. The updated notices suggest either a revised understanding of risk, broader applicability of previous issues, or new corrective actions required, demanding a prompt and detailed assessment from brand owners.

What this means for United Kingdom

UK medical device manufacturers and distributors must immediately cross-reference their Bill of Materials (BOMs) against Kimal PLC references GLB101838 – Issue 2 and GLB101836 – Issue 3. Any identified products containing these components—Namic White Star Handle Manifolds or Angiograph Control Syringes—require an urgent impact assessment. This includes potential stock quarantines, customer notifications, and logistical planning for returns or field corrections, directly affecting Q2 2026 operational budgets and sales forecasts. Regulatory teams must prepare updated technical documentation and potentially engage with the MHRA for guidance on specific recall protocols. Competitive advantages will be gained by swiftly demonstrating compliance and transparently managing any customer-facing implications, mitigating brand reputational damage.

The reissuance of these FSNs underscores the MHRA's vigilant approach to post-market surveillance. Manufacturers are advised to strengthen internal processes for monitoring regulatory alerts and communicating effectively with their supply chain partners. Proactive engagement with component suppliers regarding their own compliance frameworks is crucial to prevent similar disruptions. The cost of inaction—ranging from product recalls and market bans to legal liabilities—far outweighs the investment in robust quality management and regulatory intelligence.

Many leading brands in this category are manufactured in partnership with Supplement Factory.